Strong Selection Significantly Increases Epistatic Interactions in the Long-Term Evolution of a Protein
暂无分享,去创建一个
[1] R. Siliciano,et al. Recent trends in HIV-1 drug resistance. , 2013, Current opinion in virology.
[2] Dan S. Tawfik,et al. Robustness–epistasis link shapes the fitness landscape of a randomly drifting protein , 2006, Nature.
[3] A. Velázquez‐Campoy,et al. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. , 2003, Current drug targets. Infectious disorders.
[4] E. Ortlund,et al. Crystal Structure of an Ancient Protein: Evolution by Conformational Epistasis , 2007, Science.
[5] J. Louis,et al. HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements. , 2012, Biochemistry.
[6] Christoph Adami,et al. Annals of the New York Academy of Sciences the Use of Information Theory in Evolutionary Biology , 2022 .
[7] G. Basharin. On a Statistical Estimate for the Entropy of a Sequence of Independent Random Variables , 1959 .
[8] A. Chao,et al. Nonparametric estimation of Shannon’s index of diversity when there are unseen species in sample , 2004, Environmental and Ecological Statistics.
[9] Christopher J. Lee,et al. Distinguishing Functional Amino Acid Covariation from Background Linkage Disequilibrium in HIV Protease and Reverse Transcriptase , 2007, PloS one.
[10] F. Mammano,et al. Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.
[11] Michael M. Desai,et al. Global epistasis makes adaptation predictable despite sequence-level stochasticity , 2014, Science.
[12] B. Korber,et al. Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. , 1999, AIDS research and human retroviruses.
[13] Korbinian Strimmer,et al. Entropy Inference and the James-Stein Estimator, with Application to Nonlinear Gene Association Networks , 2008, J. Mach. Learn. Res..
[14] C. Adami,et al. Physical complexity of symbolic sequences , 1996, adap-org/9605002.
[15] C. Petropoulos,et al. Evidence for Positive Epistasis in HIV-1 , 2004, Science.
[16] Ursula Rothlisberger,et al. Drug resistance in HIV‐1 protease: Flexibility‐assisted mechanism of compensatory mutations , 2002, Protein science : a publication of the Protein Society.
[17] Bartek Wilczynski,et al. Biopython: freely available Python tools for computational molecular biology and bioinformatics , 2009, Bioinform..
[18] J. Dushoff,et al. Prevalence of Epistasis in the Evolution of Influenza A Surface Proteins , 2011, PLoS genetics.
[19] E. Freire,et al. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. , 2003, Biochemistry.
[20] B. Torbett,et al. Accessory mutations maintain stability in drug-resistant HIV-1 protease. , 2011, Journal of molecular biology.
[21] Raphail E. Krichevsky,et al. The performance of universal encoding , 1981, IEEE Trans. Inf. Theory.
[22] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[23] Mill Johannes G.A. Van,et al. Transmission Of Information , 1961 .
[24] Sebastian Bonhoeffer,et al. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase , 2011, Nature Genetics.
[25] Christoph Adami,et al. Information theory in molecular biology , 2004, q-bio/0405004.
[26] Wei Shao,et al. Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase , 2008, AIDS.
[27] D. Richman,et al. 2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.
[28] Jonathan M. Schapiro,et al. Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir , 2006, Journal of Virology.
[29] C. Schiffer,et al. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. , 2000, Journal of molecular biology.
[30] Frances H. Arnold,et al. In the Light of Evolution III: Two Centuries of Darwin Sackler Colloquium: In the light of directed evolution: Pathways of adaptive protein evolution , 2009 .
[31] D. Anastassiou. Computational analysis of the synergy among multiple interacting genes , 2007, Molecular systems biology.
[32] Sebastian Bonhoeffer,et al. Exploring the Complexity of the HIV-1 Fitness Landscape , 2012, PLoS genetics.
[33] Ga Miller,et al. Note on the bias of information estimates , 1955 .
[34] C. Adami,et al. Impact of epistasis and pleiotropy on evolutionary adaptation , 2009, Proceedings of the Royal Society B: Biological Sciences.
[35] T. Oas,et al. The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[36] W. Bialek. Biophysics: Searching for Principles , 2012 .
[37] P. Gorry,et al. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] Thanat Chookajorn,et al. Stepwise acquisition of pyrimethamine resistance in the malaria parasite , 2009, Proceedings of the National Academy of Sciences.
[39] P. Phillips. Epistasis — the essential role of gene interactions in the structure and evolution of genetic systems , 2008, Nature Reviews Genetics.
[40] D. J. Kiviet,et al. Empirical fitness landscapes reveal accessible evolutionary paths , 2007, Nature.
[41] Celia A Schiffer,et al. Covariation of amino acid positions in HIV-1 protease. , 2003, Virology.
[42] Robert B. Heckendorn,et al. Should evolutionary geneticists worry about higher-order epistasis? , 2013, Current opinion in genetics & development.
[43] L. Bourgon,et al. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. , 2005, Antiviral research.
[44] S. Yerly,et al. Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.
[45] A. Lapedes,et al. Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[46] R. Lenski,et al. Microbial genetics: Evolution experiments with microorganisms: the dynamics and genetic bases of adaptation , 2003, Nature Reviews Genetics.
[47] J. Louis,et al. Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease. , 2013, Biochemistry.
[48] Sebastian Bonhoeffer,et al. Epistasis between deleterious mutations and the evolution of recombination. , 2007, Trends in ecology & evolution.
[49] R. Hartley. Transmission of information , 1928 .
[50] Chi‐Huey Wong,et al. HIV-1 protease: mechanism and drug discovery. , 2003, Organic & biomolecular chemistry.
[51] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[52] Thomas D. Wu,et al. Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.
[53] Jesse D. Bloom,et al. Epistatically Interacting Substitutions Are Enriched during Adaptive Protein Evolution , 2014, PLoS genetics.
[54] Christoph Endres,et al. Introduction to Artificial Life , 2000, Künstliche Intell..
[55] J. da Silva. Amino Acid Covariation in a Functionally Important Human Immunodeficiency Virus Type 1 Protein Region Is Associated With Population Subdivision , 2009, Genetics.
[56] Jeffrey E. Barrick,et al. Genome evolution and adaptation in a long-term experiment with Escherichia coli , 2009, Nature.
[57] Tim F. Cooper,et al. The Environment Affects Epistatic Interactions to Alter the Topology of an Empirical Fitness Landscape , 2013, PLoS genetics.
[58] Christoph Adami,et al. Thermodynamic prediction of protein neutrality. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[59] Ronald M. Levy,et al. Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease , 2009, BMC Bioinformatics.
[60] Peter Grassberger,et al. Entropy estimation of symbol sequences. , 1996, Chaos.
[61] V. Trouplin,et al. Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug , 2000, Journal of Virology.
[62] William Bialek,et al. Entropy and Inference, Revisited , 2001, NIPS.
[63] Joachim Krug,et al. Evolutionary Accessibility of Mutational Pathways , 2011, PLoS Comput. Biol..
[64] R. Shafer,et al. Update of the drug resistance mutations in HIV-1: March 2013. , 2013, Topics in antiviral medicine.
[65] W. P. Russ,et al. Evolutionary information for specifying a protein fold , 2005, Nature.
[66] Marianne Manchester,et al. Complete mutagenesis of the HIV-1 protease , 1989, Nature.
[67] G J Williams,et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1978, Archives of biochemistry and biophysics.
[68] Charles Ofria,et al. Evolutionary dynamics, epistatic interactions, and biological information. , 2010, Journal of Theoretical Biology.
[69] A. Sousa,et al. Positive Epistasis Drives the Acquisition of Multidrug Resistance , 2009, PLoS genetics.